Eonis SMA kit
Revvity, Inc. · Decision date Sep 30, 2026
What did the FDA decide?
FDA recorded a substantial equivalence determination (SESE) for the Eonis™ SMA kit, submitted by Revvity, Inc., with a decision date of 2026-09-30 under 510(k) number K262893. The product code is QUE, regulation 21 CFR 866.5980, in the Immunology specialty. The submission's stated purpose was adding a new instrument to the test system, the Eonis Q instrument, paired with Eonis EASI software. The predicate is the Eonis SCID-SMA Kit under DEN200044.
The kit is intended for qualitative detection of SMN1 gene exon 7 as an aid in newborn screening for spinal muscular atrophy, using DNA from dried blood spots; the labeling states it is not a diagnostic test and that positive screening results should be followed by confirmatory testing. The decision summary describes a site-to-site reproducibility study across three sites and reports 100% of replicates below cut-off for the listed samples, with a 95% CI of 97.6% to 100%. The source does not state clinical sensitivity or specificity, and the decision is a clearance, not a PMA approval.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Immunology
- Decision date
- Sep 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262893
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Revvity, Inc.
- Product code
- QUE
- Decision code
- SESE
- Decision date
- Sep 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Spinal Muscular Atrophy Newborn Screening Test System.
- Applicant
- Revvity, Inc.
- Product code
- QUE
- FDA device class
- 2
FDA decision timeline
K262893 received
Application receipt date recorded by FDA.
K262893 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Revvity, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Waltham, MA
Sources and methodology
- Original FDA record: K262893
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records